Abstract
Purpose
Recently, several randomized controlled trials (RCTs) explored the effects of α-blockers with or without phosphodiesterase type 5 inhibitors (PDE5-Is) for lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). However, the results were inconsistent. We performed this meta-analysis to evaluate the role of combination therapy (α-blockers and PDE5-Is) in patients with LUTS/BPH.
Materials and methods
Databases including PubMed, Cochrane library, Web of Science, and Embase were searched for qualified RCTs. Pooled mean differences (MDs) and odds ratios (ORs) were calculated to measure the effects and adverse events in combination therapy. Moreover, subgroup analyses of ethnicity, dosage of PDE5-Is, treatment duration, and severity of LUTS/BPH were performed. In addition, trial sequential analyses (TSAs) were used to assess whether the evidence for the results was sufficient.
Results
Overall, this study identified 11 eligible RCTs, including 855 LUTS/BPH patients. Patients receiving combination therapy had better improvement in international prostate symptom score (IPSS: MD: 1.66, 95% CI − 3.03 to − 0.29), maximum urinary flow rate (Qmax: MD: 0.94, 95% CI 0.24–1.64), and international index of erectile function (IIEF: MD: 4.73, 95% CI 2.95–6.51), comparing those without PDE5-Is. Besides, subgroup analyses indicated that the effects of combination treatment were associated with ethnicity, treatment duration, and severity of LUTS/BPH. By TSA, the findings in the current study were based on sufficient evidence.
Conclusions
Our results indicated that combination therapy can significantly improve IPSS, Qmax, and IIEF in patients with LUTS/BPH. Combination therapy might be more suitable for these patients.
Similar content being viewed by others
References
Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KAO, Gravas S (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67:1099–1109. https://doi.org/10.1016/j.eururo.2014.12.038
Martin SA, Haren MT, Marshall VR, Lange K, Wittert GA (2011) Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol 29:179–184. https://doi.org/10.1007/s00345-010-0605-8
Alawamlh OAH, Goueli R, Lee RK (2018) Lower urinary tract symptoms, benign prostatic hyperplasia, and urinary retention. Med Clin N Am 102:301–311. https://doi.org/10.1016/j.mcna.2017.10.005
Ficarra V, Rossanese M, Zazzara M, Giannarini G, Abbinante M, Bartoletti R, Mirone V, Scaglione F (2014) The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep. 15:463. https://doi.org/10.1007/s11934-014-0463-9
Yuan JQ, Mao C, Wong SY, Yang ZY, Fu XH, Dai XY, Tang JL (2015) Comparative effectiveness and safety of monodrug therapies for lower urinary tract symptoms associated with benign prostatic hyperplasia: a network meta-analysis. Medicine (Baltimore). 94:e974. https://doi.org/10.1097/md.0000000000000974
Gacci M, Sebastianelli A, Spatafora P, Corona G, Serni S, De Ridder D, Gravas S, Abrams P (2018) Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base. Ther Adv Urol. 10:79–92. https://doi.org/10.1177/1756287217742837
MacDonald R, Brasure M, Dahm P, Olson CM, Nelson VA, Fink HA, Risk MC, Rwabasonga B, Wilt TJ (2018) Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review. Aging Male. https://doi.org/10.1080/13685538.2018.1434503
Thomas D, Chughtai B, Kini M, Te A (2017) Emerging drugs for the treatment of benign prostatic hyperplasia. Expert Opin Emerg Drugs. 22:201–212. https://doi.org/10.1080/14728214.2017.1369953
Djavan B, Chapple C, Milani S, Marberger M (2004) State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 64:1081–1088. https://doi.org/10.1016/j.urology.2004.07.031
van Dijk MM, de la Rosette JJ, Michel MC (2006) Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs 66:287–301
Giuliano F, Uckert S, Maggi M, Birder L, Kissel J, Viktrup L (2013) The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 63:506–516. https://doi.org/10.1016/j.eururo.2012.09.006
Taoka R, Kakehi Y (2017) The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia. Asian J Urol. 4:158–163. https://doi.org/10.1016/j.ajur.2017.02.004
Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, Gacci M, Vignozzi L, Carini M, Vannelli GB, Maggi M (2011) Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med. 8:2746–2760. https://doi.org/10.1111/j.1743-6109.2011.02416.x
Wang XH, Wang X, Shi MJ, Li S, Liu T, Zhang XH (2015) Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and alpha-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH. Asian J Androl. 17:1022–1032. https://doi.org/10.4103/1008-682x.154990
Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61:994–1003. https://doi.org/10.1016/j.eururo.2012.02.033
Oelke M, Shinghal R, Sontag A, Baygani SK, Donatucci CF (2015) Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies. J Urol 193:1581–1589. https://doi.org/10.1016/j.juro.2014.11.094
Takeda M, Yokoyama O, Yoshida M, Nishizawa O, Hirata K, Nakaoka R, Takita Y, Murakami M (2017) Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized, placebo-controlled, cross-over study. Int J Urol 24:539–547. https://doi.org/10.1111/iju.13357
Karami H, Hassanzadeh-Hadad A, Fallah-Karkan M (2016) Comparing monotherapy with tadalafil or tamsulosin and their combination therapy in men with benign prostatic hyperplasia: a randomized clinical trial. Urol J. 13:2920–2926
Fawzi A, Kamel M, Salem E, Desoky E, Omran M, Elgalaly H, Sakr A, Maarouf A, Khalil S (2017) Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: a randomised, double-blind, placebo-controlled trial. Arab J Urol. 15:53–59. https://doi.org/10.1016/j.aju.2016.11.001
Kumar S, Kondareddy C, Ganesamoni R, Nanjappa B, Singh SK (2014) Randomized Controlled trial to assess the efficacy of the combination therapy of alfuzosin and tadalafil in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Low Urin Tract Symptoms. 6:35–40. https://doi.org/10.1111/luts.12016
Regadas RP, Reges R, Cerqueira JB, Sucupira DG, Josino IR, Nogueira EA, Jamacaru FV, de Moraes MO, Silva LF (2013) Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial. Int Urol Nephrol 45:39–43. https://doi.org/10.1007/s11255-012-0317-7
Abolyosr A, Elsagheer GA, Abdel-Kader MS, Hassan AM, Abou-Zeid AM (2013) Evaluation of the effect of sildenafil and/or doxazosin on Benign prostatic hyperplasia-related lower urinary tract symptoms and erectile dysfunction. Urol Ann. 5:237–240. https://doi.org/10.4103/0974-7796.120293
Gacci M, Vittori G, Tosi N, Siena G, Rossetti MA, Lapini A, Vignozzi L, Serni S, Maggi M, Carini M (2012) A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 9:1624–1633. https://doi.org/10.1111/j.1743-6109.2012.02718.x
Ozturk MI, Kalkan S, Koca O, Gunes M, Akyuz M, Karaman MI (2012) Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms. Andrologia. 44(Suppl 1):791–795. https://doi.org/10.1111/j.1439-0272.2011.01268.x
Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O, Atan A (2010) Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol 28:17–22. https://doi.org/10.1007/s00345-009-0484-z
Bechara A, Romano S, Casabe A, Haime S, Dedola P, Hernandez C, Rey H (2008) Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med. 5:2170–2178. https://doi.org/10.1111/j.1743-6109.2008.00940.x
Kaplan SA, Gonzalez RR, Te AE (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51:1717–1723. https://doi.org/10.1016/j.eururo.2007.01.033
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269, W64
Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340:c869. https://doi.org/10.1136/bmj.c869
Zhang J, Yang B, Xiao W, Li X, Li H (2018) Effects of testosterone supplement treatment in hypogonadal adult males with T2DM: a meta-analysis and systematic review. World J Urol. https://doi.org/10.1007/s00345-018-2256-0
Li X, Shen M, Cai H, Liu K, Liu Y, Huang Z, Liang C, Deng X, Ye J, Zou Q, Li J (2016) Association between manganese superoxide dismutase (MnSOD) polymorphism and prostate cancer susceptibility: a meta-analysis. Int J Biol Markers 31:e422–e430. https://doi.org/10.5301/jbm.5000188
Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, Gluud LL, Als-Nielsen B, Gluud C (2009) Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol 38:276–286. https://doi.org/10.1093/ije/dyn179
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials. 7:177–188
DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 28:105–114. https://doi.org/10.1016/j.cct.2006.04.004
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634
Uckert S, Kuthe A, Jonas U, Stief CG (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol. 166:2484–2490
Francis SH, Busch JL, Corbin JD, Sibley D (2010) cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 62:525–563. https://doi.org/10.1124/pr.110.002907
Yokoyama O, Igawa Y, Takeda M, Yamaguchi T, Murakami M, Viktrup L (2015) Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action. Ther Adv Urol. 7:249–264. https://doi.org/10.1177/1756287215589238
Kolontarev K, Govorov A, Kasyan G, Priymak D, Pushkar D (2016) Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors. Cent Eur J Urol 69:398–403. https://doi.org/10.5173/ceju.2016.879
Shim SR, Kim JH, Chang IH, Shin IS, Hwang SD, Kim KH, Yoon SJ, Song YS (2016) Is tamsulosin 0.2 mg effective and safe as a first-line treatment compared with other alpha blockers? A meta-analysis and a moderator focused study. Yonsei Med J 57:407–418. https://doi.org/10.3349/ymj.2016.57.2.407
Acknowledgements
This work is supported by the grant from the National Natural Science Foundation of China (81671488) and the Beijing Natural Science Foundation (Grant No. 7162152).
Funding
This study was funded by the National Natural Science Foundation of China (81671488) and the Beijing Natural Science Foundation (Grant no. 7162152).
Author information
Authors and Affiliations
Contributions
HJL: project development and manuscript writing. JZZ: data collection and manuscript writing. XL: data collection and data analysis. BY: data collection and data analysis. CW: data collection. YHF.: data analysis.
Corresponding author
Ethics declarations
Conflict of interest
Hongjun Li has received research grants from the National Natural Science Foundation of China (81671488) and the Beijing Natural Science Foundation (Grant no. 7162152).
Informed consent
Informed consent was obtained from all individual participants included in the study.
Research involving human participants and/or animals
For this type of study formal consent is not required. This article does not contain any studies with animals performed by any of the authors.
Electronic supplementary material
Below is the link to the electronic supplementary material.
345_2018_2370_MOESM1_ESM.tif
Figure S1 Subgroup analyses of effects of combination therapy versus a-blockers alone by assessment of IPSS. A–D Subgroup analyses by ethnicity, treatment period, severity of LUTS, and dosage of PDE5-Is, respectively (TIFF 1091 kb)
345_2018_2370_MOESM2_ESM.tif
Figure S2 Subgroup analyses of effects of combination therapy versus a-blockers alone by assessment of Qmax. A–C Subgroup analyses by treatment period, severity of LUTS, and dosage of PDE5-Is, respectively (TIFF 438 kb)
345_2018_2370_MOESM3_ESM.tif
Figure S3 Subgroup analyses of effects of combination therapy versus a-blockers alone by assessment of PVR. A, B Subgroup analyses by treatment period and dosage of PDE5-Is, respectively (TIFF 476 kb)
345_2018_2370_MOESM4_ESM.tif
Figure S4 Subgroup analyses of effects of combination therapy versus a-blockers alone by assessment of IIEF. A, B Subgroup analyses by treatment period and dosage of PDE5-Is, respectively (TIFF 500 kb)
345_2018_2370_MOESM5_ESM.tif
Figure S5 Sensitivity of each included study in this meta-analysis. A–D indicated sensitivity analyses of IPSS, Qmax, PVR, and IIEF, respectively (TIFF 550 kb)
345_2018_2370_MOESM6_ESM.tif
Figure S6 Funnel plots of the publication bias. A–D indicated funnel plots of IPSS, Qmax, PVR, and IIEF, respectively 6 (TIFF 265 kb)
Rights and permissions
About this article
Cite this article
Zhang, J., Li, X., Yang, B. et al. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. World J Urol 37, 143–153 (2019). https://doi.org/10.1007/s00345-018-2370-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-018-2370-z